NY-ALKEGEN
8.6.2022 19:52:05 CEST | Business Wire | Press release
Alkegen, a leading specialty materials platform creating transformational battery materials, today announced they will be exhibiting at the upcoming AABC Europe Conference in Mainz, and The Battery Show Europe in Stuttgart, Germany. Alkegen’s Battery Group focuses on delivering battery innovation with advanced materials for Lithium Ion Battery (LiB) thermal barriers and electrical protection, battery separator technology, and revolutionary silicon fiber anode battery material (SiFAB®) that enables greater energy density, faster charges, and longer battery life in electric vehicles, portable electronics and energy storage systems. Alkegen, formerly Unifrax and Lydall, is a one-of-a-kind specialty materials platform dedicated to human health and sustainability.
The technical capabilities of the Alkegen Battery Group support customer partnerships with a global engineering team, deep technical expertise, and customer collaboration. These unique capabilities allow for a globally coordinated team of engineers and designers with a dedicated presence in each region, solutions designed for easy installation and handling, and scalable, customized solutions that meet budgets and optimize performance.
Alkegen’s range of technical capabilities includes Design, Testing, Prototyping and Serial Production. The global design team employs 3D modelling software to collaborate with customers and optimize form, fit and function. Thermal, mechanical, environmental and compression testing are used for part validation and new product development. The engineering team prototypes both in-pack and in-cell solutions once designed to validate product functionality. Finally, Alkegen’s global footprint of IATF certified sites and engineering teams support scale up through regional production locations in Europe, North America and the Asia-Pacific region.
Alkegen’s transformational battery portfolio includes both in-cell and in-pack solutions. In-cell solutions such as separators and additives to improve cell performance and safety include SiFAB, Alkegen’s fibrous silicon anode battery material with ultra-high capacity that enables greater energy density and is highly scalable. SiFAB technology was launched last year and will scale to production this summer. Also from Alkegen, Inovion™ is a high surface area fibrous separator paper that promotes rapid ion exchange. Alkegen also offers several in-pack solutions including high-temperature lightweight products designed to reduce thermal runaway propagation along with providing mechanical, electrical and thermal protections within the battery pack. Innovative product solutions also include FyreBlocker™ LiB, AlkeGel™ Aerogel Materials and FyreWrap® LiB performance materials. These in-cell and in-pack innovations have valuable functions in numerous industries and applications from portable electronics, e-mobility, to robotics.
”Alkegen’s Battery Group is focused on delivering the latest battery technologies and developments from our long-standing tradition of innovating unique material technologies to create superior new products and solutions for our customers’ greatest challenges,” explained Adam Kelsall, General Manager, Alkegen Battery Group. “This transformational portfolio presents numerous opportunities for Alkegen with applications spanning EV lithium-ion battery fire protection, creating greater battery energy density and delivering longer battery life in both electric vehicles and consumer electronics,” said Kelsall.
Alkegen will be available to discuss these innovative new battery materials and more during the 2022 AABC Europe Show June 13-15, in Mainz, and The Battery Show June 28-30, in Stuttgart, Germany. Interested attendees can sign up for sessions with our Alkegen Battery Group experts to meet during the conferences by contacting us at info@alkegen.com .
About Alkegen
Alkegen, formerly Unifrax and Lydall Materials, creates high performance specialty materials used in advanced applications including electric vehicles, energy storage, filtration, fire protection and high-temperature insulation, among many others. Alkegen is vertically integrated across multiple process technology platforms designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our mission of helping the world breathe easier, live greener and go further than ever before. Alkegen has 75 manufacturing facilities operating in 12 countries and employs 9,000+ employees globally. More information is available at www.alkegen.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608006046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom